Identifying patients at high risk for neutropenic complications during chemotherapy for metastatic breast cancer with doxorubicin or pegylated liposomal doxorubicin: The development of a prediction model

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 31, Issue 4, 2008, Pages 369-374

  Dranitsaris, George ^g   Rayson, Daniel ^a   Vincent, Mark ^b   Chang, Jose ^c   Gelmon, Karen ^d   Sandor, David ^e   Reardon, Greg ^f  

^a QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^b LONDON REGIONAL CANCER PROGRAM   (Canada)

^c McLaughlin Durham Regional Cancer Centre   (Canada)

^d BRITISH COLUMBIA CANCER AGENCY   (Canada)

^e Touro College and University System   (United States)

^f Informagenics LLC   (United States)

^g Statistical Consultant   (Canada)

Author keywords

Anthracyclines; Breast Cancer; Doxorubicin; Neutropenia; Prediction; Risk

Indexed keywords

ANTHRACYCLINE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; MACROGOL DERIVATIVE;

ADJUVANT THERAPY; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER PATIENT; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSAGE FORM COMPARISON; FEBRILE NEUTROPENIA; FEMALE; FUNCTIONAL STATUS; HEART FAILURE; HIGH RISK PATIENT; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NEUTROPHIL COUNT; PATIENT SELECTION; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; BONE TUMOR; BREAST TUMOR; CANCER STAGING; CHEMICALLY INDUCED DISORDER; CONTROLLED CLINICAL TRIAL; LIVER TUMOR; LUNG TUMOR; METASTASIS; MIDDLE AGED; PATHOLOGY; PHASE 3 CLINICAL TRIAL; PROGNOSIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL MODEL; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; BREAST NEOPLASMS; DOXORUBICIN; FEMALE; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; MIDDLE AGED; MODELS, STATISTICAL; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEUTROPENIA; POLYETHYLENE GLYCOLS; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 55449115686     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e318165c01d     Document Type: Article

References (27)

1. Chan S, Friedrichs K, Noel D, et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol. 1999;17:2341-2354.
2. Paridaens R, Biganzoli L, Bruning P, et al. Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over. J Clin Oncol. 2000;18:724-733.
3. Wolff D, Culakova E, Poniewierski MS, et al. Predictors of chemotherapy-induced neutropenia and its complications: results from a prospective nationwide registry. J Support Oncol. 2005;(6 Suppl 4):24-25.
4. Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer. 2004;100:228-237.
5. Caggiano V, Weiss RV, Rickert TS, et al. Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer. 2005;103:1916-1924.
6. Lyman GH. Guidelines of the National Comprehensive Cancer Network on the use of myeloid growth factors with cancer chemotherapy: a review of the evidence. J Natl Compr Canc Netw. 2005;3:557-571.
7. Aapro MS, Cameron DA, Pettengell R, et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer. 2006;42:2433-2453.
8. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidencebased clinical practice guideline. J Clin Oncol. 2006;24:3187-3205.
9. Lyman GH. Risk assessment in oncology clinical practice. From risk factors to risk models. Oncology. 2003;(11 Suppl 11):8-13.
10. Lyman GH, Lyman CH, Agboola O. Risk models for predicting chemotherapy-induced neutropenia. Oncologist. 2005;10:427-437.
11. Silber JH, Fridman M, Dipaola RS, et al. First-cycle blood counts and subsequent neutropenia, dose reduction or delay in early stage breast cancer therapy. J Clin Oncol. 1998;16:2392-2400.
12. Rivera E, Erder MH, Moore TL, et al. Targeted filgrastim support in patients with early stage breast carcinoma. Cancer. 2003;98:222-228.
13. Dranitsaris G, Clemons M, Verma S, et al. The development of a prediction tool for anemia in breast cancer patients receiving adjuvant chemotherapy. Lancet Oncol. 2005;6:856-863.
14. Dranitsaris G, Shah A, Spirovski B, et al. Severe diarrhea in patients with advanced colorectal cancer receiving FOLFOX of FOLFIRI chemotherapy: the development of a risk prediction tool. Clin Colorectal Cancer. 2007;6:367-373.
15. O'Brien ME, Wigler N, Inbar M, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for firstline treatment of metastatic breast cancer. Ann Oncol. 2004;15:440-449.
16. George SL. Identification and assessment of prognostic factors. Semin Oncol. 1988;15:462-471.
17. Walter LC, Brand RJ, Counse SR, et al. Development and validation of a prognostic index for 1-year mortality in older adults after hospitalization. JAMA. 2001;285:2987-2894.
18. Allison PD. Logistic Regression Using the SAS System: Theory and Application. Cary, NC: SAS Institute, Inc.; 1999:179-216.
19. Rabe-Hesketh S, Everitt B. Statistical Analysis Using Stata. Chapman & Hall/CRC; 2000:119-136.
20. Steyerberg EW, Eijkemans MJ, Harrell FE Jr, et al. Prognostic modeling with logistic regression analysis: in search of sensible strategies in small data sets. Med Decis Making. 2001;21:45-56.
21. Steyerberg EW, Harrell FE Jr, Borsboom GJ, et al. Internal validation of predictive models: efficiency of some procedures for logistic regression analysis. J Clin Epidemiol. 2001;54:774-781.
22. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982;143:29-36.
23. McNeil BJ, Hanley JA. Statistical approaches to the analysis of receiver operating characteristic (ROC) curves. Med Decis Making. 1984;4:137-150.
24. Krupp NL, Weinstein G, Chalian A. Validation of a transfusion prediction model in head and neck cancer surgery. Arch Otolaryngol Head Neck Surg. 2003;129:1297-1302.
25. Kloess M, Wunderlich Trumper L, et al. Predicting hematotoxicity in multicycle chemotherapy. Blood. 1999;94(Suppl 1):87a.
26. Katz MH. Multivariable analysis: a primer for readers of the medical literature. Ann Intern Med. 2003;138:644-650.
27. Verma S, Wong NS, Trudeau M, et al. Survival differences observed in metastatic breast cancer patients treated with capecitabine when compared with vinorelbine after pretreatment with anthracycline and taxane. Am J Clin Oncol. 2007;30:297-302.